Late-stage, or Phase III, trials are ongoing to confirm the findings, researchers said, and to test whether the vaccine protects against infection with SARS-CoV-2 in a broad range of people, including people with underlying health conditions.
But experts have cautioned against using data exclusively from emergency use programme, without comparable results from a clinical trial-standard control group, to determine a vaccine's effectiveness.
Pollard discussed progress in the late-stage trials as Oxford released a study based on earlier research that found the vaccine was well tolerated and produced a strong immune response in people over 70.
Other COVID-19 vaccines have also been shown to generate immune responses in older adults, but it can be hard to compare results between different studies.
They show that older adults aged 56-69 and over 70 had a similar immune response to younger adults aged 18-55. "Our findings show that CoronaVac is capable of inducing a quick antibody response within four weeks of immunization by giving two doses of the vaccine at a 14-day interval", the researchers said in the journal.
Investigator at the Oxford Vaccine Group and consultant physician Dr Maheshi Rasamy said the fact that older people had a better response to the vaccine was a positive step forward.
Klay Thompson suffers right leg injury, will undergo MRI
In a devastating turn of events, this will no longer happen as Thompson recently tore his Achilles during a practice session . Based on the type of tear, Thompson has been told to expect that he will make a full recovery, a source tells ESPN.
Justin Trudeau has spoken out about securing doses of the Moderna COVID-19 vaccine in Canada.
The news about Moderna's vaccine candidate is encouraging - and we've secured tens of millions of doses for Canadians. No serious adverse health events related to ChAdOx1 nCoV-19 were seen in these volunteers.
Christmas definitely came early for all of us with the astonishingly good results reported in huge clinical trials of Pfizer, Moderna and Sputnik COVID vaccines.
"What this could mean is that in the future when we're looking to boost people's responses, we might need to do it more often in older people than we do with younger people, but we're not thinking that we're going to need to boost people a few times a year as we do with the flu vaccine".
Russian Federation has also reached a grim milestone, surpassing 2 million total coronavirus cases on Thursday after reporting 23,610 new cases over a 24-hour period, including 463 deaths. The virus is genetically engineered to carry a little piece of the coronavirus into the body and train the immune system to recognize and attack it. "Further assessment of the efficacy of this vaccine is warranted in all age groups and individuals with co-morbidities", noted the study. "They must also be safe, effective in preventing disease and/or transmission, and provide at least six months of protection for people frequently exposed to the virus - such as healthcare workers".